Programmed death-1 and its ligand are novel immunotolerant molecules expressed on leukemic B cells in chronic lymphocytic leukemia

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Grzywnowicz, Maciej ^a   Zaleska, Joanna ^a   Mertens, Daniel ^b,c   Tomczak, Waldemar ^a   Wlasiuk, Paulina ^a   Kosior, Kamila ^a   Piechnik, Agnieszka ^a   Bojarska Junak, Agnieszka ^a   Dmoszynska, Anna ^a   Giannopoulos, Krzysztof ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b UNIVERSITY OF ULM   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CD40 LIGAND; INTERLEUKIN 4; MESSENGER RNA; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CD40 ANTIGEN; PDCD1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL ISOLATION; CELL SURFACE; CELLULAR DISTRIBUTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; EXON; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD274; ANTIGENS, CD40; B-LYMPHOCYTES; FEMALE; HUMANS; INTERLEUKIN-4; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84859817335     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035178     Document Type: Article

References (40)

1. Caligaris-Cappio F, Ghia P, (2008) Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 26: 4497-4503.
2. Finger LR, Pu J, Wasserman R, Vibhakar R, Louie E, et al. (1997) The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors. Gene 197: 177-187.
3. Kuppers R, (2005) Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 5: 251-262.
4. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK, (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94: 1848-1854.
5. Stamatopoulos K, Belessi C, Moreno C, Boudjograh M, Guida G, et al. (2007) Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. Blood 109: 259-270.
6. Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, et al. (2008) Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 111: 1524-1533.
7. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, et al. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192: 1027-1034.
8. Blank C, Kuball J, Voelkl S, Wiendl H, Becker B, et al. (2006) Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro. Int J Cancer 119: 317-327.
9. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, et al. (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2: 261-268.
10. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, et al. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800.
11. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A 99: 12293-12297.
12. Keir ME, Butte MJ, Freeman GJ, Sharpe AH, (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26: 677-704.
13. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, et al. (2004) PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 574: 37-41.
14. Zhang L, Gajewski TF, Kline J, (2009) PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 114: 1545-1552.
15. Dong H, Chen L, (2003) B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl) 81: 281-287.
16. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, et al. (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 8: 765-772.
17. Damle RN, Temburni S, Calissano C, Yancopoulos S, Banapour T, et al. (2007) CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. Blood 110: 3352-3359.
18. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, et al. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343: 1910-1916.
19. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ, (2006) Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 30: 802-810.
20. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM, (2006) Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107: 3639-3646.
21. Shimauchi T, Kabashima K, Nakashima D, Sugita K, Yamada Y, et al. (2007) Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma. Int J Cancer 121: 2585-2590.
22. Yamamoto R, Nishikori M, Kitawaki T, Sakai T, Hishizawa M, et al. (2008) PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111: 3220-3224.
23. Roncador G, Garcia Verdes-Montenegro JF, Tedoldi S, Paterson JC, Klapper W, et al. (2007) Expression of two markers of germinal center T cells (SAP and PD-1) in angioimmunoblastic T-cell lymphoma. Haematologica 92: 1059-1066.
24. Xerri L, Chetaille B, Serriari N, Attias C, Guillaume Y, et al. (2008) Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol 39: 1050-1058.
25. Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, et al. (2003) Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 170: 1257-1266.
26. Richendollar BG, Pohlman B, Elson P, Hsi ED, (2011) Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma. Hum Pathol 42: 552-557.
27. Nielsen C, Ohm-Laursen L, Barington T, Husby S, Lillevang ST, (2005) Alternative splice variants of the human PD-1 gene. Cell Immunol 235: 109-116.
28. He XH, Xu LH, Liu Y, (2005) Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain. Acta Pharmacol Sin 26: 462-468.
29. Wan B, Nie H, Liu A, Feng G, He D, et al. (2006) Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 177: 8844-8850.
30. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL, (2004) SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol 173: 945-954.
31. Damle RN, Ghiotto F, Valetto A, Albesiano E, Fais F, et al. (2002) B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 99: 4087-4093.
32. Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, et al. (2003) ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 101: 4944-4951.
33. Okazaki T, Maeda A, Nishimura H, Kurosaki T, Honjo T, (2001) PD-1 immunoreceptor inhibits B cell receptor-mediated signaling by recruiting src homology 2-domain-containing tyrosine phosphatase 2 to phosphotyrosine. Proc Natl Acad Sci U S A 98: 13866-13871.
34. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ, (2007) The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 8: 239-245.
35. Carreras J, Lopez-Guillermo A, Roncador G, Villamor N, Colomo L, et al. (2009) High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 27: 1470-1476.
36. Iwai Y, Terawaki S, Honjo T, (2005) PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int Immunol 17: 133-144.
37. Hirano F, Kaneko K, Tamura H, Dong H, Wang S, et al. (2005) Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 65: 1089-1096.
38. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, et al. (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439: 682-687.
39. Berger R, Rotem-Yehudar R, Slama G, Landes S, Kneller A, et al. (2008) Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 14: 3044-3051.
40. Giannopoulos K, Schmitt M, Kowal M, Wlasiuk P, Bojarska-Junak A, et al. (2008) Characterization of regulatory T cells in patients with B-cell chronic lymphocytic leukemia. Oncol Rep 20: 677-682.